Key result
Stepwise ablation with vein of Marshall ethanol infusion yields ~82% 12-month arrhythmia freedom in persistent AF.
Why the study?
The optimal ablation strategy to modify left atrial substrate in persistent AF remains elusive, despite cumulative data suggesting an incremental benefit of adding vein of Marshall ethanol infusion to PVI.
Does a stepwise ablation approach incorporating vein of Marshall ethanol infusion prevent atrial arrhythmia recurrence in patients with persistent atrial fibrillation?
Observational (n=66)
No
Does a stepwise ablation approach incorporating vein of Marshall ethanol infusion prevent atrial arrhythmia recurrence in patients with persistent atrial fibrillation?
A novel stepwise ablation strategy incorporating vein of Marshall ethanol infusion, PVI, and substrate modification is feasible, safe, and associated with an 82% rate of freedom from atrial arrhythmias at 12 months in patients with persistent AF.
May support stepwise ablation incorporating vein of Marshall ethanol in persistent AF; leaves open confirmation of benefit in randomized trials.
Introduction: Apart from pulmonary vein isolation (PVI), several step-by-step procedures that aim to modify left atrial substrate have been proposed for the ablation of persistent atrial fibrillation (AF), yet the optimal strategy remains elusive. There are cumulative data suggesting an incremental benefit of adding vein of Marshall (VOM) ethanol infusion to PVI in patients with persistent AF. We sought to evaluate the feasibility and efficacy of a novel stepwise ablation approach, incorporating a VOM alcoholization step, for persistent AF. Methods: In this single-center study, we prospectively enrolled 66 consecutive patients with symptomatic persistent AF and failure of at least one antiarrhythmic drug (ADD). The ablation procedure consisted of (i) PVI, (ii) left atrial segmentation with VOM ethanol infusion and the deployment of linear radiofrequency lesions across the roof and the mitral isthmus and (iii) electrogram-based ablation of dispersion zones. The first two steps were performed in all patients, whereas the third step was carried out only in those still in AF at the end of the second step. Atrial tachycardias during the procedure were mapped and ablated. At the end of the procedure, cavotricuspid isthmus ablation was additionally performed in all patients. The primary endpoint was 12-month freedom from AF and atrial tachycardia after a single procedure and an initial three-month blanking period. Results: = 0.04). One patient developed a pericardial tamponade and another a minor groin hematoma. Conclusion: A novel stepwise approach, including a step of ethanol infusion in the VOM, is feasible, safe and provides a high rate of sinus rhythm maintenance at 12 months in patients with persistent AF.
No takes yet. Share an insight, caveat, or question.
Sousonis et al. (2023) conducted an observational in Symptomatic persistent atrial fibrillation (n=66). Stepwise ablation incorporating vein of Marshall ethanol infusion was evaluated on 12-month freedom from AF and atrial tachycardia after a single procedure and an initial 3-month blanking period. A novel stepwise ablation approach incorporating vein of Marshall ethanol infusion achieved an 82% rate of 12-month freedom from atrial arrhythmias after a single procedure in persistent AF patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: